...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of International Medical Research >Comparison of the Therapeutic Effect, Tolerance and Safety of Ketazolam and Diazepam Administered for Six Months to Out-Patients with Chronic Anxiety Neurosis
【24h】

Comparison of the Therapeutic Effect, Tolerance and Safety of Ketazolam and Diazepam Administered for Six Months to Out-Patients with Chronic Anxiety Neurosis

机译：头孢唑仑和地西p对慢性焦虑神经症门诊患者治疗六个月的疗效，耐受性和安全性比较

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Recently, it has been argued that benzodiazepines may not be safe or efficacious beyond 3 months continuous dosage. This study was designed to provide data regarding efficacy, safety, possible tolerance development, and possible withdrawal effects of administering ketazolam and diazepam for a 6-month period. Chronic anxiety patients were screened for participation according to specific inclusion and exclusion criteria. Of 139 patients, forty-four terminated prematurely for non-drug related reasons and are not included in the analysis. Of the ninety-five patients remaining, sixty-three were on ketazolam, and thirty-two on diazepam. Efficacy parameters included the Hamilton Anxiety Rating Scale, Physician's Global Impressions, Target Symptoms, Self-Rating Symptom Scale, and Patient's Global Impressions. Patients were evaluated weekly for the first month except for Week 3, and then seen bi-weekly and rated monthly. The results of the study showed that ketazolam was as efficacious as diazepam in treating anxiety and resulted in fewer side-effects. No adverse effects were noted in either group. Both benzodiazepines were safe and well-tolerated. No tolerance or withdrawal effects were noted. The average doses were ketazolam Week 4 (50.0 mg), Week 24 (66.14 mg) and diazepam Week 4 (26.33 mg) and Week 24 (33.0 mg). An increase in anxiety occurred in a significant number of patients after termination of either drug. By 2 weeks after the last dose many patients were free of anxiety and did not require further treatment. These results demonstrate that benzodiazepines are safe and efficacious for at least 6 months of continuous dosage.
机译：最近，有人争辩说，连续三个月以上服用苯二氮卓类药物可能并不安全或无效。这项研究旨在提供有关使用酮唑仑和地西for治疗6个月的疗效，安全性，可能的耐受性发展以及可能的戒断作用的数据。根据特定的纳入和排除标准筛选了慢性焦虑症患者的参与情况。在139例患者中，有44例因与药物无关的原因提前终止治疗，因此未纳入分析。在其余的九十五名患者中，六十三名患者服用了克他唑仑，三十二名患者使用了地西epa。疗效参数包括汉密尔顿焦虑量表，医师的整体印象，目标症状，自评症状量表和患者的整体印象。除第3周外，对患者的第一个月每周进行一次评估，然后每两周进行一次检查并每月进行评估。研究结果表明，酮咯唑仑在治疗焦虑症方面与地西epa一样有效，且副作用较少。两组均未发现不良反应。两种苯二氮卓均安全且耐受良好。没有发现耐受性或戒断作用。平均剂量为ketazolam第4周（50.0 mg），第24周（66.14 mg）和地西epa第4周（26.33 mg）和第24周（33.0 mg）。终止使用任何一种药物后，大量患者中的焦虑增加。在最后一次服药后2周，许多患者摆脱了焦虑，无需进一步治疗。这些结果表明，苯并二氮杂卓连续至少6个月是安全有效的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号